

A biomarker for diagnosing pulmonary hypertension

April 13 2016



A clinical study demonstrating the safety of the PulmoBind biomarker and the ability of the PulmoBind tomography (SPECT) scan to clearly show abnormal results in patients with pulmonary hypertension. Credit: Thinkstock.

During the annual meeting of the American College of Cardiology (ACC) in Chicago, a researcher from the Montreal Heart Institute (MHI) presented the results of a phase II clinical study demonstrating the safety



of the PulmoBind biomarker and the ability of the PulmoBind tomography (SPECT) scan to clearly show abnormal results in patients with pulmonary hypertension.

The work of the team headed by Dr. Jocelyn Dupuis has led to the development of the first safe, sensitive and non-invasive molecular imaging agent designed for <u>early diagnosis</u> and monitoring of pulmonary hypertension. Dr. Dupuis was able to demonstrate that PulmoBind could replace the tests currently used in clinical trials to establish an early diagnosis and monitor treatment efficacy. "This breakthrough brings great hope to patients with pulmonary hypertension because of the lifechanging impact of benefiting from earlier treatment," says principal investigator, Dr. Jocelyn Dupuis. Pulmonary hypertension (PH) is a common, potentially life- threatening disease characterized by a progressive narrowing of the blood vessels in the lungs. It causes a gradual increase in shortness of breath, which leads to significant disability. There is currently no cure for pulmonary hypertension, and the development of effective medication is complicated by the lack of non-invasive tests that can screen for the disease at an early stage and monitor its progression. That is why this discovery gives so much hope to people with this disease. "I wish to express my gratitude to CQDM for believing in our project's potential from the outset. Its clinical progress would not have been possible without their substantial financing of \$2.8 M," added Dr. Dupuis.

PulmoBind is a new radiopharmaceutical product developed jointly by Dr. François Harel from the MHI's Nuclear Medicine Department and Alain Fournier, PhD, a peptide chemist at INRS–Institut Armand-Frappier. "There is currently no equivalent to PulmoBind capable of performing a functional imaging of pulmonary circulation. We take pride in this product for which we carried out all stages of development, from the basic research to its human application. We were able to achieve this using the state-of-the-art equipment at the MHI's Nuclear



Medicine Department," explains Dr. François Harel, nuclear cardiology specialist.

According to Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute Research Centre and professor of medicine at Université de Montréal, "this discovery and the development of PulmoBind by Dr. Jocelyn Dupuis and Dr. Francois Harel could truly change the lives of patients with <u>pulmonary hypertension</u> by improving early diagnosis and personalized monitoring. Once again, the Montreal Heart Institute has demonstrated its leadership position in cardiovascular precision medicine with this remarkable advancement."

CQDM is pleased with the results yielded by the projects to date. "We are extremely proud to have supported this project from the very beginning. We also salute the contribution of mentor Michael Klimas from Merck when adapting the PulmoBind marker to positron emission tomography (PET) scans. Results are very impressive and point to a bright future," said Diane Gosselin, CEO of CQDM.

These results will lead to a phase III study extending three years and involving 350 patients across 10 centres in North America.

Provided by University of Montreal

Citation: A biomarker for diagnosing pulmonary hypertension (2016, April 13) retrieved 6 May 2024 from <u>https://medicalxpress.com/news/2016-04-biomarker-pulmonary-hypertension.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.